ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CD73
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CD73
3
trial(s) found.
NCT07165067
Advanced
Phase 1
Recruiting
A Phase 1, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients With Solid Tumors. (
AP601-101
)
bispecific CD73/4-1BB antibody
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3121 - Richmond - Epworth Freemasons Hospital
QLD
4217 - Benowa - Pindara Private Hospital
NCT06162572
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression (
SPLFIO-174
)
Cemiplimab
S095018
S095024
S095029
anti-CD73 monoclonal antibody
anti-NKG2A monoclonal antibody
anti-PD-1 monoclonal antibody
anti-TIM3 monoclonal antibody
cancer therapy
cancer therapy,CD73-targeting
cancer therapy,NKG2A-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIM3-targeting
immune checkpoint blockade
immune checkpoint blockade,CD73-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIM3-targeting
immuno-oncology therapy,CD73-targeting
immuno-oncology therapy,NKG2A-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIM3-targeting
+ anti-CD73 monoclonal antibody
Non-small cell lung cancer
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3844 - Traralgon - Latrobe Regional Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05205109
Advanced
Phase 1
Recruiting
A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (
ATG-037-001
)
CD73 inhibitor
anti-PD-1 monoclonal antibody
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit (TERMINATED)
WA
6009 - Nedlands - One Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Recruitment Country and State
NSW (3)
VIC (3)
QLD (2)
SA (1)
WA (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (1)
Trial Type
Advanced (3)
Cancer Therapy Class
CD73
100%
PD-1
67%
PD-1/PD-L1
67%
4-1BB
33%
NKG2A
33%
TIM3
33%
Facility
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
4217 - Benowa - Pindara Private Hospital (2)
3121 - Richmond - Epworth Freemasons Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
6009 - Nedlands - One Clinical Research (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy